Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time

Journal of Trauma - Injury, Infection and Critical Care

Volumn 67, Issue 2, 2009, Pages 266-275

  Park, Myung S ^a,d   Martini, Wenjun Z ^a   Dubick, Michael A ^a   Salinas, Jose ^a   Butenas, Saulius ^b   Kheirabadi, Bijan S ^a   Pusateri, Anthony E ^a   Vos, Jeffrey A ^c   Guymon, Charles H ^a   Wolf, Steven E ^a   Mann, Kenneth G ^b   Holcomb, John B ^a  

^a US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Deep vein thrombosis; Pulmonary embolism; Thromboelastograph

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 11; D DIMER; ENOXAPARIN; FIBRINOGEN; PROTEIN C;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; BLUNT TRAUMA; BURN; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HOSPITALIZATION; HUMAN; HYPERCOAGULABILITY; INJURY SEVERITY; INTENSIVE CARE UNIT; LABORATORY TEST; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; THROMBOELASTOGRAPHY;

ADULT; ANTITHROMBIN III; CASE-CONTROL STUDIES; FACTOR XIA; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROTEIN C; PROTHROMBIN TIME; PULMONARY EMBOLISM; THROMBELASTOGRAPHY; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; WOUNDS AND INJURIES;

EID: 69349105802     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/TA.0b013e3181ae6f1c     Document Type: Article

References (61)

1. Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma. 2003;54:1127-1130.
2. Kaufmann CR, Dwyer KM, Crews JD, Dols SJ, Trask AL. Usefulness of thrombelastography in assessment of trauma patient coagulation. J Trauma. 1997;42:716-720.
3. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N Engl J Med. 1994; 331:1601-1606. (Pubitemid 24372057)
4. Essell JH, Martin TJ, Salinas J, Thompson JM, Smith VC. Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1993;7:410-415. (Pubitemid 23231393)
5. Schreiber MA. Coagulopathy in the trauma patient. Curr Opin Crit Care. 2005;11:590-597.
6. Kang Y. Thromboelastography in liver transplantation. Semin Thromb Hemost. 1995;21(Suppl 4):34-44.
7. Spiess BD, Gillies BS, Chandler W, Verrier E. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth. 1995;9:168-173.
8. Spiess BD. Thromboelastography and cardiopulmonary bypass. Semin0 Thromb Hemost. 1995;21(Suppl 4):27-33.
9. Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg. 1999;88:312-319. (Pubitemid 29070189)
10. Plotkin AJ, Wade CE, Jenkins DH, et al. A reduction in clot formation rate and strength assessed by thrombelastography is indicative of transfusion requirements in patients with penetrating injuries. J Trauma. 2008;64(2 Suppl):S64-S68.
11. Watts DD, Trask A, Soeken K, Perdue P, Dols S, Kaufmann C. Hypothermic coagulopathy in trauma: effect of varying levels of hypothermia on enzyme speed, platelet function, and fibrinolytic activity. J Trauma. 1998;44:846-854. (Pubitemid 28233032)
12. Schreiber MA, Differding J, Thorborg P, Mayberry JC, Mullins RJ. Hypercoagulability is most prevalent early after injury and in female patients. J Trauma. 2005;58:475-480. (Pubitemid 40365805)
13. Drost AC, Burleson DG, Cioffi WG Jr, Jordan BS, Mason AD Jr, Pruitt BA Jr. Plasma cytokines following thermal injury and their relationship with patient mortality, burn size, and time postburn. J Trauma. 1993; 35:335-339.
14. Gando S, Nakanishi Y, Tedo I. Cytokines and plasminogen activator inhibitor-1 in posttrauma disseminated intravascular coagulation: relationship to multiple organ dysfunction syndrome. Crit Care Med. 1995; 23:1835-1842.
15. Utter GH, Owings JT, Jacoby RC, Gosselin RC, Paglieroni TG. Injury induces increased monocyte expression of tissue factor: factors associated with head injury attenuate the injury-related monocyte expression of tissue factor. J Trauma. 2002;52:1071-1077.
16. Drake TA, Ruf W, Morrissey JH, Edgington TS. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J Cell Biol. 1989;109:389-395. (Pubitemid 19180145)
17. Neumann FJ, Ott I, Marx N, et al. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol. 1997;17:3399-3405. (Pubitemid 28028548)
18. Schwager I, Jungi TW. Effect of human recombinant cytokines on the induction of macrophage procoagulant activity. Blood. 1994;83:152-160. (Pubitemid 24016527)
19. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost. 1991;66:67-79.
20. Bouma BN, Griffin JH. Human blood coagulation factor XI: purification, properties, and mechanism of activation by activated factor XII. J Biol Chem. 1977;252:6432-6437.
21. Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med. 2006;203:513-518.
22. Minnema MC, Peters RJ, de Winter R, et al. Activation of clotting factors XI and IX in patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2000;20:2489-2493. (Pubitemid 30825087)
23. Coppola R, Cristilli P, Cugno M, Ariëns RA, Mari D, Mannucci PM. Measurement of activated factor XII in health and disease. Blood Coagul Fibrinolysis. 1996;7:530-535. (Pubitemid 26294882)
24. Butenas S, Undas A, Gissel MT, Szuldrzynski K, Zmudka K, Mann KG. Factor XIa and tissue factor activity in patients with coronary artery disease. Thromb Haemost. 2008;99:142-149.
25. Jordan RE, Oosta GM, Gardner WT, Rosenberg RD. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem. 1980;255:10081-10090.
26. Olson ST, Shore JD. Binding of high affinity heparin to antithrombin III: characterization of the protein fluorescence enhancement. J Biol Chem. 1981;256:11065-11072. (Pubitemid 12181590)
27. Bock SC. Antithrombin III and heparin cofactor II. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:235-248.
28. van't Veer C, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J Biol Chem. 1997;272: 4367-4377.
29. Baugh RJ, Broze GJ Jr, Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem. 1998;273:4378-4386. (Pubitemid 28103174)
30. Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood. 1988;71:335-343.
31. Esmon CT. The anticoagulant and anti-inflammatory roles of the protein C anticoagulant pathway. J Autoimmun. 2000;15:113-116. (Pubitemid 30707578)
32. Esmon C. The protein C pathway. Crit Care Med. 2000;28(9 Suppl): S44-S48.
33. Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost. 2005;3:2039-2043. (Pubitemid 43086062)
34. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638-1652.
35. Giovannini I, Chiarla C, Giuliante F, Vellone M, Nuzzo G. Modulation of plasma fibrinogen levels in acute-phase response after hepatectomy. Clin Chem Lab Med. 2004;42:261-265. (Pubitemid 38477519)
36. Attar S, Boyd D, Layne E, McLaughlin J, Mansberger AR, Cowley RA. Alterations in coagulation and fibrinolytic mechanisms in acute trauma. J Trauma. 1969;9:939-965.
37. Martini WZ, Wolf SE, Chinkes DL, et al. Accelerated fibrinogen metabolism and coagulation in severely burned adults. Poster session presented at: 14th Congress of the International Society of Burn Injury, Montreal, Quebec, September 7-11, 2008.
38. Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med. 1996;335:701-707. (Pubitemid 26287356)
39. Cho SD, Morris MS, Underwood SA, Watters JM, Schreiber MA. Thromboelastography vs anti-factor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients. Presented at: 67th annual meeting of the American Association for the Surgery of Trauma, Maui, Hawaii, September 24-27, 2008.
40. Geerts WH, Bergqvist D, Pineo GF, et al; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 Suppl):381S-453S.
41. Pusateri AE, Park MS. Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma. Crit Care. 2005; 9(Suppl 5):S15-S24. (Pubitemid 43173684)
42. Kheirabadi BS, Crissey JM, Deguzman R, Holcomb JB. In vivo bleeding time and in vitro thrombelastography measurements are better indicators of dilutional hypothermic coagulopathy than prothrombin time. J Trauma. 2007;62:1352-1359. (Pubitemid 46918729)
43. Engelman DT, Gabram SG, Allen L, Ens GE, Jacobs LM. Hypercoagulability following multiple trauma. World J Surg. 1996;20:5-10.
44. Milic DJ, Pejcic VD, Zivic SS, et al. Coagulation status and the presence of postoperative deep vein thrombosis in patients undergoing laparoscopic cholecystectomy. Surg Endosc. 2007;21:1588-1592.
45. Radl R, Kastner N, Aigner C, Portugaller H, Schreyer H, Windhager R. Venous thrombosis after hallux valgus surgery. J Bone Joint Surg Am. 2003;85:1204-1208. (Pubitemid 36764926)
46. Caprini JA, Natonson RA. Postoperative deep vein thrombosis: current clinical considerations. Semin Thromb Hemost. 1989;15:244-249. (Pubitemid 19249873)
47. Arcelus JI, Traverso CI, Caprini JA. Thromboelastography for the assessment of hypercoagulability during general surgery. Semin Thromb Hemost. 1995;21(Suppl 4):21-26.
48. Caprini JA, Zuckerman L, Cohen E, Vagher JP, Lipp V. The identification of accelerated coagulability. Thromb Res. 1976;9:167-180.
49. Caprini JA, Arcelus JI, Goldshteyn S, Hoffman KN, Coats RW 2nd. Thromboelastography: measuring statistical probabilities. Semin Thromb Hemost. 1995;21(Suppl 4):14-20. (Pubitemid 26015176)
50. Alkjaersig N, Fletcher AP, Peden JC Jr, Monafo WW. Fibrinogen catabolism in burned patients. J Trauma. 1980;20:154-159.
51. Curreri PW, Wilterdink ME, Baxter CR. Characterization of elevated fibrin split products following thermal injury. Ann Surg. 1975;181:157-160.
52. Summaria L, Sandesara J, Yang G, Vagher JP, Caprini JA. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-chain-streptokinase complex in the dog model using pre-titered doses. Thromb Haemost. 1986;56:71-79. (Pubitemid 16015920)
53. Van Riper DF, Horrow JC, Osborne D. Is the thromboelastograph a clinically useful predictor of blood loss after bypass [abstract]? Anesthesiology. 1990;73: Abstract no. A1206.
54. Whitten CW, Allison PH, Latson TW, et al. Thromboelastographic fibrinolysis does not correlate with levels of d-dimers after cardiopulmonary bypass [abstract]. Anesthesiology. 1991;75: Abstract no. A431.
55. Baglia FA, Walsh PN. Thrombin-mediated feedback activation of factor XI on the activated platelet surface is preferred over contact activation by factor XIIa or factor XIa. J Biol Chem. 2000;275:20514-20519. Retraction in: J Biol Chem. 2007;282:29067.
56. Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science. 1991;253:909-912. (Pubitemid 21917236)
57. Yun TH, Baglia FA, Myles T, et al. Thrombin activation of factor XI on activated platelets requires the interaction of factor XI and platelet glycoprotein Ib alpha with thrombin anion-binding exosites I and II, respectively. J Biol Chem. 2003;278:48112-48119. Partial retraction in: J Biol Chem. 2007;282:29067. (Pubitemid 37523263)
58. Owings JT, Bagley M, Gosselin R, Romac D, Disbrow E. Effect of critical injury on plasma antithrombin activity: low antithrombin levels are associated with thromboembolic complications. J Trauma. 1996;41:396-405. (Pubitemid 26318066)
59. Cotton BA, Guy JS, Morris JA Jr, Abumrad NN. The cellular, metabolic, and systemic consequences of aggressive fluid resuscitation strategies. Shock. 2006;26:115-121.
60. Kiraly LN, Differding JA, Enomoto TM, et al. Resuscitation with normal saline (NS) vs. lactated ringers (LR) modulates hypercoagulability and leads to increased blood loss in an uncontrolled hemorrhagic shock swine model. J Trauma. 2006;61:57-64. (Pubitemid 44098316)
61. Rhee P, Burris D, Kaufmann C, et al. Lactated Ringer's solution resuscitation causes neutrophil activation after hemorrhagic shock. J Trauma. 1998;44:313-319. (Pubitemid 28124170)